Phylogica’s biological “peptide” vaccine has performed the best in coaxing an immune response against HSV during animal testing, with 75% of the mice treated with its peptides mated to a common HSV antigen showing no detectable signs of the virus. The company will now pit its peptide vaccine against Swiss company Amal Therapeutics’ zebra CPP with results expected in the first quarter of 2019.
Related Data & Insights
-
PYC Therapeutics
Closing price for the last 90 trading daysPowered by Morningstar ® -
Rank Company # 71st Seafarms Group $25.48m 72nd Westoz Investment Company $24.68m 73rd - Yowie Group $22.49m 74th PYC Therapeutics $22.06m 198 public companies - industrial WA ranked by total revenue
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
15 Aug 2024
Trial approval for PYC Therapeutics
31 Jul 2024
Seven newcomers in BN30 refresh
24 May 2024
PYC Therapeutics hit FDA milestone
14 Mar 2024
PYC taps investors for $75m
02 Jan 2024
Nedlands company joins Google in AI project
11 May 2023